Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05141357 · ClinicalTrials.gov registry record · Phase 2
A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by HUYABIO International.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT05141357 is a Phase 2 study that was terminated before completion, run by HUYABIO International. The registered enrollment target is 5 participants.
The verdict
NCT05141357, a Phase 2 study, was terminated before completion, sponsored by HUYABIO International.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
A Phase 2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Pembrolizumab for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
- DRUG HBI-8000 in combination with pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05141357
The ClinicalTrials.gov registry entry for NCT05141357 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HUYABIO International, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HBI-8000 in combination with pembrolizumab is the first listed.
NCT05141357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05141357 about?
NCT05141357 is a clinical study titled "A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer". A Phase 2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Pembrolizumab for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
What is the current status of trial NCT05141357?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2022-02-15. Estimated completion is 2023-04-19.
What interventions are being tested in trial NCT05141357?
The interventions under investigation include: HBI-8000 in combination with pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT05141357?
This trial is sponsored by HUYABIO International, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.